RecruitingPhase 1NCT07579208

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma


Sponsor

M.D. Anderson Cancer Center

Enrollment

36 participants

Start Date

Aug 21, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

To find the best method of administering NK cells in patients with recurrent glioblastoma.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NK Cells and a drug called NK Cells for people with chimera antigen receptor (car), egfrviii, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNK Cells

Given by Ommaya Reservoir

DRUGNK Cells

Given by IV


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07579208


Related Trials